

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Erenumab for preventing migraine**

**Batch 55**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The company suggested that limiting the population in the scope to people with episodic migraine, and not including those with chronic migraine, could lead to equality issues.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This is not an equality issue as it does not disproportionately affect people with a protected characteristic.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The definition of the population in the scope was broadened to people with migraine, which includes people with episodic or chronic migraine in order to reflect the anticipated marketing authorisation, and clinical trial evidence.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

|  |
|--|
| to the matrix been made?                         |
| No additional stakeholders have been identified. |

**Approved by Associate Director (name):** Helen Knight

**Date:** 27/02/2018